Article Type: Generic

Genome Canada well positioned for future growth as Meulien departs for top IMI job

This week marks the end of a key chapter in Canadian genomics research with the departure of Dr. Pierre Meulien. After five years as president and CEO of Genome Canada and three and a half years as chief scientific officer (CSO) of Genome British Columbia, Meulien is heading to Brussels to take the helm of the Innovative Medicines Initiative (IMI).

RSC joins chorus calling for chief scientific advisor to federal government

The Royal Society of Canada (RSC) is urging the government to catch up with the rest of the world’s wealthiest nations and establish a chief scientific advisor (CSA). The recommendation is one of several contained in a position paper designed to unlock the full value of science in the Canadian economy and society.

Analysis: Ron Freedman, CEO, Research Infosource Inc.

Emerging trends in federal S&T spending
By Ron Freedman

In late May, Statistics Canada released its most recent data on federal government S&T spending. There was plenty to chew on and one clear paradox emerged.